| Non-Small Cell Lung Carcinoma
Alecensa vs Mektovi
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Alecensa vs Mektovi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsMektovi has a higher rate of injection site reactions vs Alecensa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Mektovi but not Alecensa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Alecensa
Mektovi
At A Glance
Oral
Twice daily
ALK/RET tyrosine kinase inhibitor
Oral
Twice daily
MEK inhibitor
Indications
- Non-Small Cell Lung Carcinoma
- melanoma
- Non-Small Cell Lung Carcinoma
Dosing
Non-Small Cell Lung Carcinoma (adjuvant) 600 mg orally twice daily with food for a total of 2 years or until disease recurrence or unacceptable toxicity following tumor resection of ALK-positive NSCLC (tumors >= 4 cm or node positive).
Non-Small Cell Lung Carcinoma (metastatic) 600 mg orally twice daily with food until disease progression or unacceptable toxicity; reduce to 450 mg orally twice daily for severe hepatic impairment (Child-Pugh C).
melanoma 45 mg orally twice daily in combination with encorafenib; reduce to 30 mg orally twice daily for patients with moderate or severe hepatic impairment.
Non-Small Cell Lung Carcinoma 45 mg orally twice daily in combination with encorafenib.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Hepatotoxicity, constipation, fatigue, myalgia, edema, rash, cough
Serious Hepatotoxicity, ILD/pneumonitis, renal impairment, bradycardia, severe myalgia and CPK elevation, hemolytic anemia, pneumonia
Most common (>=25%) fatigue, nausea, diarrhea, vomiting, abdominal pain, musculoskeletal pain, visual impairment, constipation, dyspnea, rash, cough
Serious hemorrhage, diarrhea, anemia, dyspnea, pneumonia, arrhythmia, device related infection, edema, myocardial infarction, pleural effusion
Pharmacology
Alectinib is a tyrosine kinase inhibitor that targets ALK and RET; it inhibits ALK phosphorylation and ALK-mediated activation of downstream signaling proteins STAT3 and AKT, with the major active metabolite M4 showing similar in vitro potency and activity against multiple mutant forms of ALK, including mutations identified in NSCLC tumors that have progressed on crizotinib.
Binimetinib is a reversible inhibitor of MEK1 and MEK2, upstream regulators of the ERK pathway; combined with encorafenib it targets two different kinases in the RAS/RAF/MEK/ERK pathway for greater anti-proliferative and anti-tumor activity in BRAF mutation-positive tumors.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Alecensa
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Mektovi
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Alecensa
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (8/8)
Mektovi
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (0/8)
Humana
Alecensa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Mektovi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAlecensa Access Solutions Bridge Program
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0/fillfill
Mektovi Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AlecensaView full Alecensa profile
MektoviView full Mektovi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.